Successful use of the left portal vein as graft for middle hepatic vein reconstruction in left hemihepatectomy: preliminary experience on six cases.


Journal

World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544

Informations de publication

Date de publication:
09 Nov 2019
Historique:
received: 28 06 2019
accepted: 04 10 2019
entrez: 11 11 2019
pubmed: 11 11 2019
medline: 28 4 2020
Statut: epublish

Résumé

The purpose of this research was to assess the feasibility of reconstructing the middle hepatic vein (MHV) with resected left portal vein during left hemihepatectomy. From January 2014 to January 2018, six patients received left hemihepatectomy combined with MHV reconstruction using the resected left portal vein in West China Hospital. We reviewed the clinical data including patient details, surgical technique, graft patency, and operative results. All six patients underwent left hemihepatectomy for liver tumors located at left hepatocaval confluence. In these patients, MHV was resected due to tumor invading and reconstructed using the resected left portal vein as graft. The mean operating time was 316 min. Two patients developed complications: one experienced bile leakage and one experienced pleural effusion. No patient developed vascular graft complications. All the grafts remained unobstructed, and no local tumor recurrence occurred during the observation period of 13-41 months. Our results indicated that the left portal vein was a safe graft for hepatic vein reconstruction. In addition, left hemihepatectomy combined with middle hepatic vein resection and reconstruction using the left portal vein can be performed safely to treat liver tumors located at hepatocaval confluence.

Sections du résumé

BACKGROUND BACKGROUND
The purpose of this research was to assess the feasibility of reconstructing the middle hepatic vein (MHV) with resected left portal vein during left hemihepatectomy.
METHODS METHODS
From January 2014 to January 2018, six patients received left hemihepatectomy combined with MHV reconstruction using the resected left portal vein in West China Hospital. We reviewed the clinical data including patient details, surgical technique, graft patency, and operative results.
RESULTS RESULTS
All six patients underwent left hemihepatectomy for liver tumors located at left hepatocaval confluence. In these patients, MHV was resected due to tumor invading and reconstructed using the resected left portal vein as graft. The mean operating time was 316 min. Two patients developed complications: one experienced bile leakage and one experienced pleural effusion. No patient developed vascular graft complications. All the grafts remained unobstructed, and no local tumor recurrence occurred during the observation period of 13-41 months.
CONCLUSIONS CONCLUSIONS
Our results indicated that the left portal vein was a safe graft for hepatic vein reconstruction. In addition, left hemihepatectomy combined with middle hepatic vein resection and reconstruction using the left portal vein can be performed safely to treat liver tumors located at hepatocaval confluence.

Identifiants

pubmed: 31706343
doi: 10.1186/s12957-019-1719-0
pii: 10.1186/s12957-019-1719-0
pmc: PMC6842513
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

187

Références

Hepatobiliary Pancreat Dis Int. 2016 Dec;15(6):593-601
pubmed: 27919848
Case Rep Gastroenterol. 2017 May 19;11(2):320-328
pubmed: 28626378
J Gastrointest Surg. 2019 Jun;23(6):1227-1231
pubmed: 30783956
World J Surg Oncol. 2014 Apr 23;12:113
pubmed: 24758399
J Surg Case Rep. 2016 Apr 13;2016(4):null
pubmed: 27076622
Hepat Oncol. 2014 Jan;1(1):53-65
pubmed: 30190941
Ann Surg. 2018 Jul;268(1):127-133
pubmed: 28288065
Liver Transpl. 2019 Sep 11;:null
pubmed: 31507067
Langenbecks Arch Surg. 2004 Apr;389(2):110-3
pubmed: 15004752
J Hepatobiliary Pancreat Sci. 2017 Sep;24(9):511-519
pubmed: 28660678
Br J Surg. 2011 Dec;98(12):1742-51
pubmed: 22034181
HPB (Oxford). 2016 Dec;18(12):1031-1038
pubmed: 27665239
Langenbecks Arch Surg. 2014 Apr;399(4):461-71
pubmed: 24663295
World J Surg. 2000 Mar;24(3):377-82
pubmed: 10658076
Oncotarget. 2016 Jun 7;7(23):34703-51
pubmed: 27167195

Auteurs

Tao Lv (T)

Department of Liver Surgery, Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Ling Xiang Kong (LX)

Department of Liver Surgery, Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Jiayin Yang (J)

Department of Liver Surgery, Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. yangjiayinhx1@163.com.

Hong Wu (H)

Department of Liver Surgery, Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Tianfu Wen (T)

Department of Liver Surgery, Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Li Jiang (L)

Department of Liver Surgery, Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Jian Yang (J)

Department of Liver Surgery, Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH